ClinicalTrials.gg
Active, not recruitingNCT06118281ARTEMISUpdated Sep 9, 2026

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

A Phase 3 interventional study of Ziltivekimab and Placebo in Cardiovascular Risk and Acute Myocardial Infarction (AMI), sponsored by Novo Nordisk A/S. Active, not recruiting at 836 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 440 studies in Myocardial Infarction with a site in United States — 41 open to participants now, 65 under way, 9 of them phase 3. Myocardial Infarction · United States.

Planned enrollment
20th of 301
10,000 · median 160
Started
2024
with 14 others
Phase 3
67 of 440
4 open now
Primary completion
2027-01
later than 24 of 64 live
Registered
406th of 440
by date

Among the 440 studies in Myocardial Infarction with a site in United States, this one is the 20th largest by planned enrollment of the 301 interventional ones that give a count, is one of 15 that started in 2024, is one of 67 in phase 3, reaches primary completion later than 24 of the 64 other live ones, and was the 406th registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

41 of the 440 studies in Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Myocardial Infarction with a site in United States, or all of them as a file.
02

Study summary

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

03

Conditions studied

  • Cardiovascular Risk
  • Acute Myocardial Infarction (AMI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion:

  • Age 18 years or above at the time of signing the .
  • Hospitalisation for acute myocardial infarction with evidence of type 1 myocardial infarction (MI) by invasive angiography performed at site with percutaneous coronary intervention (PCI) capabilities.
  • ST-segment elevation myocardial infarction (STEMI) with all the following: a) Relevant onset of symptoms suggestive of cardiac ischaemia within 12 hours before hospitalisation, at the investigator's discretion.

    b) (ECG)-changes (in the absence of left ventricular hypertrophy or left bundle branch block): ST-segment elevation at the J point in at least two contiguous leads greater than or equal 0.25 (millivolt) mV in men less than 40 years, greater than or equal 0.2 mV in men greater than or equal 40 years, or greater than or equal 0.15 mV in women in leads V2-V3; and/or greater than or equal 0.1 mV in all other leads.

OR

  • Non-ST-segment myocardial infarction with all the following: a) Relevant onset of symptoms suggestive of cardiac ischaemia within 24 hours before hospitalisation, at the investigator's discretion. b) Rise and/or fall in car-diac troponin I or T with at least one value above the 99th percentile upper reference limit.
  • Possibility for both randomisation and administration of the loading dose of study intervention as early as possible after invasive procedure, and latest within 36 hours of hospitalisation (time 0) for STEMI, and latest within 72 hours of hospitalisation (time 0) for NSTEMI.
  • Presence of at least one of the following criteria confirmed based on the participant's medical records and/or medical history interview: a) Any prior MI. b) Prior coronary revascularisation. c) Diabetes mellitus treated with ongoing glucose-lowering agent(s). d)Known chronic kidney disease (CKD) (estimated (eGFR) greater than or equal to 15 and less than 60 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2). e) Prior ischaemic stroke. f) Known carotid disease or peripheral artery disease in the lower extremities. g) Multivessel coronary artery disease (current/prior). h) For STEMI patients only: anterior MI at index acute myocardial infarction (AMI)

Key exclusion:

  • Use of fibrinolytic therapy for treatment of the current AMI.
  • Chronic heart failure classified as being in (NYHA) Class IV.
  • Ongoing haemodynamic instability defined as any of the following: a) Killip Class III or IV. b) Sustained and/or symptomatic hypotension (systolic blood pressure less than 90 millimeters of mercury (mmHg)).
  • Severe kidney impairment defined as any of the following: a) eGFR less than 15 mililitre per minute per 1.73 m\^2. b) Chronic haemodialysis or peritoneal dialysis.
  • Known (ALT) greater than 8 x (reference range) (ULN).
  • Severe hepatic disease defined as at least one of the following: a) Previously known or current hepatic encephalopathy (clinical evaluation). b) Previously known or current ascites (clinical eval-uation). c) Jaundice (clinical evaluation). d) Previous oesophageal/gastric variceal bleeding. c) Known hepatic cirrhosis.
  • Major cardiac surgical (including but not restricted to coronary artery bypass graft surgery (CABG)), non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days or any major surgical procedure planned at the time of randomisation or as treatment for the current AMI (CABG). Deferred (staged)percutaneous coronary intervention for a non-culprit vessel identified during the current AMI is allowed.
  • Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.
  • Known (acute or chronic) or .
  • History or evidence of untreated latent tuberculosis (TB) such as (but not limited to): a) History of a positive TB test or chest X-ray compatible with latent TB; and TB treatment initiated less than 28 days prior to randomisation. b) Participants with TB risk factors but unwilling to undergo TB treatment if confirmed positive for latent TB based on central laboratory test at baseline (visit 2).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10,000 participants (estimated)

Study arms

  • Experimental
    Ziltivekimab

    Participants will receive an initial loading dose of ziltivekimab Dose 1 subcutaneously (s.c.) as early as possible after invasive procedure, and latest within 36 hours of hospitalisation for ST-elevation myocardial infarction (STEMI) and within 48 hours of hospitalisation for non-ST-elevation myocardial infarction (NSTEMI), followed by ziltivekimab Dose 2 s.c. once-monthly during the treatment period (estimated up to 2 years) added to standard of care.

    Drug: Ziltivekimab

  • Experimental
    Placebo ziltivekimab

    Participants will receive placebo matched to ziltivekimab at an initial loading dose subcutaneously (s.c.) as early as possible after invasive procedure, and latest within 36 hours of hospitalisation for STEMI and latest within 48 hours of hospitalisation for NSTEMI, followed by placebo matched to ziltivekimab s.c. once-monthly during the treatment period (estimated up to 2 years) added to standard of care.

    Drug: Placebo

Interventions

  • Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.

  • DrugPlacebo

    Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal stroke

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

Secondary outcomes

  1. Number of CV death, non-fatal MI, non-fatal stroke

    Measured as count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  2. Time to first occurrence of a composite MACE endpoint consisting of: All-cause mortality, Non-fatal MI, Non-fatal stroke

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  3. Number of all-cause mortality, non-fatal MI, non-fatal stroke

    Measured as count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  4. Time to first occurrence of non-fatal MI

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  5. Time to first occurrence of MI (fatal and non-fatal)

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  6. Time to first occurrence of non-fatal stroke

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  7. Time to first occurrence of stroke (fatal and non-fatal)

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  8. Time to first occurrence of a 3-component coronary MACE endpoint comprising:CV death, Non-fatal MI, Ischaemia-driven coronary revascularisation

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  9. Time to first occurrence of a 5-component expanded MACE endpoint comprising: CV death, Non-fatal MI, Non-fatal stroke, Ischaemia-driven coronary revascularisation, Heart failure (HF) hospitalisation or urgent HF visit

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  10. Number of CV death, non-fatal MI, non-fatal stroke, ischaemia-driven coronary revascularisation, or HF hospitalisation or urgent HF visit

    Measired as count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  11. Time to first occurrence of a 3-component HF endpoint comprising: CV death, HF hospitalisation or urgent HF visit, Outpatient HF visit

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  12. Number of CV deaths, HF hospitalisation or urgent HF visits or outpatient HF visit

    Measured in count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  13. Time to first occurrence of a 2-component HF endpoint comprising: CV death, HF hospitalisation or urgent HF visit

    Measured as months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  14. Number of CV deaths, HF hospitalisation or urgent HF visits

    Measured in count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  15. Time to first occurrence of a 2-component expanded HF endpoint comprising: HF hospitalisation or urgent HF visit, Outpatient HF visit

    Measured as months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  16. Number of HF hospitalisation or urgent HF visit or outpatient HF visit

    Measured as count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  17. Number of outpatient HF visit

    Measured in count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  18. Time to occurrence of CV death

    Measured as months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  19. Time to occurrence of all-cause death

    Measured as months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  20. Time to first occurrence of 6-component vascular event endpoint: CV death, Non-fatal MI, Non-fatal stroke, Ischaemia-driven coronary revascularisation, Non-coronary revascularisation procedure, Any other non-coronary ischaemic event excluding stroke

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  21. Number of CV death, non-fatal MI and non-fatal stroke, ischaemia-driven coronary revascularisation, non-coronary revascularisation procedure, or any other non-coronary ischaemic event excluding stroke

    Measured as count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  22. Number of ischaemia-driven coronary revascularisation

    Measured as count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  23. Time to first occurrence of ischaemia-driven coronary revascularisation or any non-coronary revascularisation

    Measured in months.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  24. Number of ischaemia-driven coronary revascularisation or any non-coronary revascularisation

    Measured as count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  25. Number of cardiovascular hospitalisations

    Measured as count of events.

    Time frame: From randomisation (month 0) to 1 month/ 30 days

  26. Number of cardiovascular hospitalisations

    Measured as count of events.

    Time frame: From randomisation (month 0) to 12 months

  27. Number of hospitalisations with infection as primary cause or death due to infection

    Measured as count of events.

    Time frame: From randomisation (month 0) to end-of-study (up to 25 months)

  28. Change in high-sensitivity C-reactive protein (hs-CRP)

    Measured as ratio to baseline.

    Time frame: From randomisation (month 0) to 6 months

07

Study locations

836 sites

Showing the first 100 of 836 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jan 2027, 31 months after the start.

Of 57 phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 7, 2023
StartActual
Jun 25, 2024
Primary completionEst.
Jan 29, 2027
CompletionEst.
Jan 29, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06118281
Lead sponsor
Novo Nordisk A/S
Collaborators
Duke Clinical Research Institute
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Jun 25, 2024
Primary completion
Jan 29, 2027 (estimated)
Completion
Jan 29, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion